Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment

scientific article published on 11 March 2008

Careful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1018018880
P356DOI10.1186/1479-0556-6-10
P932PMC publication ID2276190
P698PubMed publication ID18334017
P5875ResearchGate publication ID5518271

P2093author name stringYves Beuzard
Daniel Scherman
Emmanuel Payen
Emmanuelle E Fabre
Pascal Bigey
P2860cites workLong-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats.Q45876557
Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primatesQ45879163
Hematology of a murine beta-thalassemia: a longitudinal studyQ45889556
Improvement of mouse beta-thalassemia by electrotransfer of erythropoietin cDNA.Q57670350
A mouse model for β-thalassemiaQ70168656
Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapyQ70903398
Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parametersQ72390216
Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransferQ73595843
Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulationQ80828818
High-efficiency gene transfer into skeletal muscle mediated by electric pulsesQ35123357
Iron Deficiency and Erythropoiesis: New Diagnostic ApproachesQ35538677
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risksQ36096717
Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporationQ37210391
Long-term expression of erythropoietin from myoblasts immobilized in biocompatible and neovascularized microcapsulesQ40413623
Gene therapy for renal anemia in mice with polycystic kidney using an adenovirus vector encoding the human erythropoietin geneQ40961003
Comparison of various expression plasmids for the induction of immune response by DNA immunization.Q41092520
Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activatorsQ42516387
Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblastsQ42524485
Regulated expression of erythropoietin from an AAV vector safely improves the anemia of beta-thalassemia in a mouse model.Q44426807
Human erythropoietin gene therapy for patients with chronic renal failureQ45044565
pCOR: a new design of plasmid vectors for nonviral gene therapyQ45861925
Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vectorQ45866962
Autoimmune anemia in macaques following erythropoietin gene therapyQ45871935
P921main subjectgene therapyQ213901
P304page(s)10
P577publication date2008-03-11
P1433published inGenetic Vaccines and TherapyQ15767223
P1476titleCareful adjustment of Epo non-viral gene therapy for beta-thalassemic anaemia treatment
P478volume6

Reverse relations

cites work (P2860)
Q37646523Emerging technologies in the delivery of erythropoietin for therapeutics
Q36431079Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression
Q45864162Minimal doses of a sequence-optimized transgene mediate high-level and long-term EPO expression in vivo: challenging CpG-free gene design
Q37924090New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials

Search more.